Compare CMT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMT | SGMT |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | 1239 | N/A |
| Industry | Electronic Components | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 169.4M |
| IPO Year | 1996 | 2021 |
| Metric | CMT | SGMT |
|---|---|---|
| Price | $25.70 | $9.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $24.00 | ★ $26.13 |
| AVG Volume (30 Days) | 20.3K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $284,290,000.00 | $2,000,000.00 |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $95.63 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $16.60 | $4.50 |
| 52 Week High | $28.69 | $10.01 |
| Indicator | CMT | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 69.36 |
| Support Level | $22.80 | $6.62 |
| Resistance Level | $28.67 | N/A |
| Average True Range (ATR) | 1.44 | 0.59 |
| MACD | 0.16 | 0.20 |
| Stochastic Oscillator | 75.84 | 79.77 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.